Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10327824" target="_blank" >RIV/00216208:11110/16:10327824 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/16:33160649
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(16)30154-1" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(16)30154-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(16)30154-1" target="_blank" >10.1016/S1470-2045(16)30154-1</a>
Alternative languages
Result language
angličtina
Original language name
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Original language description
Background: The randomised phase 3 TURANDOT trial compared two approved bevacizumab-containing regimens for HER2-negative metastatic breast cancer in terms of efficacy, safety, and quality of life. The interim analysis did not confirm non-inferior overall survival (stratified hazard ratio [HR] 1.04; 97.5% repeated CI [RCI] -oo to 1.69). Here we report final results of our study aiming to show non-inferior overall survival with first-line bevacizumab plus capecitabine versus bevacizumab plus paclitaxel for locally recurrent or metastatic breast cancer.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Oncology
ISSN
1470-2045
e-ISSN
—
Volume of the periodical
17
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
1230-1239
UT code for WoS article
000382398700037
EID of the result in the Scopus database
2-s2.0-84994530470